Form 4: Gilead Sciences' Chief Medical Officer, Merdad Parsey, Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Merdad Parsey, Chief Medical Officer of Gilead Sciences, exercised stock options and sold shares of common stock on November 6, 2024, according to a Form 4 filing with the SEC.
Summary
- On November 6, 2024, Merdad Parsey, the Chief Medical Officer of Gilead Sciences, exercised non-qualified stock options to acquire 25,000 shares of Gilead Sciences common stock at a price of $57.92 per share.
- Simultaneously, Parsey sold 20,590 shares at $91.50 and 5,000 shares at $91.50.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9, 2023.
- Following these transactions, Parsey directly owns 99,599 shares of Gilead Sciences common stock and 121,670 derivative securities (non-qualified stock options).
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by a company executive under a pre-arranged plan. It doesn't necessarily indicate positive or negative sentiment about the company's prospects.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any inside information at the time of the trades.
Comparison to Industry Standards
- Executive compensation packages often include stock options as incentives.
- The vesting schedule of the options (25% after one year, then 6.25% quarterly) is a common practice.
- Rule 10b5-1 trading plans are widely used by corporate insiders to manage their stock transactions and avoid accusations of insider trading; many companies such as Pfizer, Amgen, and Johnson & Johnson have executives who utilize similar plans.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/09/2023 | Date of adoption of Rule 10b5-1 trading plan |
| 11/06/2024 | Date of stock option exercise and stock sales |
| 11/07/2024 | Date of Form 4 filing |
| 03/10/2032 | Expiration date of non-qualified stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.